Trioleyl Pyridinium, a Cationic Transfection Agent for the Lipofection of Therapeutic Oligonucleotides into Mammalian Cells.
PPRH
apoptosis
cancer
cell viability
delivery
hairpin
mammalian cell
stable transfection
therapeutic oligonucleotide
transfection agent
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 Jan 2023
27 Jan 2023
Historique:
received:
02
01
2023
revised:
18
01
2023
accepted:
20
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
One of the most significant limitations that therapeutic oligonucleotides present is the development of specific and efficient delivery vectors for the internalization of nucleic acids into cells. Therefore, there is a need for the development of new transfection agents that ensure a proper and efficient delivery into mammalian cells. We describe the synthesis of 1,3,5-tris[(4-oelyl-1-pyridinio)methyl]benzene tribromide (TROPY) and proceeded to the validation of its binding capacity toward oligonucleotides, the internalization of DNA into the cells, the effect on cell viability, apoptosis, and its capability to transfect plasmid DNA. The synthesis and chemical characterization of TROPY, which can bind DNA and transfect oligonucleotides into mammalian cells through clathrin and caveolin-mediated endocytosis, are described. Using a PPRH against the antiapoptotic TROPY is an efficient transfecting agent that allows the delivery of therapeutic oligonucleotides, such as PPRHs and plasmid DNA, inside mammalian cells.
Sections du résumé
BACKGROUND
BACKGROUND
One of the most significant limitations that therapeutic oligonucleotides present is the development of specific and efficient delivery vectors for the internalization of nucleic acids into cells. Therefore, there is a need for the development of new transfection agents that ensure a proper and efficient delivery into mammalian cells.
METHODS
METHODS
We describe the synthesis of 1,3,5-tris[(4-oelyl-1-pyridinio)methyl]benzene tribromide (TROPY) and proceeded to the validation of its binding capacity toward oligonucleotides, the internalization of DNA into the cells, the effect on cell viability, apoptosis, and its capability to transfect plasmid DNA.
RESULTS
RESULTS
The synthesis and chemical characterization of TROPY, which can bind DNA and transfect oligonucleotides into mammalian cells through clathrin and caveolin-mediated endocytosis, are described. Using a PPRH against the antiapoptotic
CONCLUSIONS
CONCLUSIONS
TROPY is an efficient transfecting agent that allows the delivery of therapeutic oligonucleotides, such as PPRHs and plasmid DNA, inside mammalian cells.
Identifiants
pubmed: 36839742
pii: pharmaceutics15020420
doi: 10.3390/pharmaceutics15020420
pmc: PMC9960667
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerio de Ciencia e Innovacion
ID : PID2021-122271OB-I00
Références
Dev Cell. 2006 Jun;10(6):839-50
pubmed: 16740485
Mol Pharm. 2015 Mar 2;12(3):867-77
pubmed: 25615267
Biochem Pharmacol. 2018 Sep;155:8-20
pubmed: 29940174
Diagn Pathol. 2012 May 18;7:52
pubmed: 22607367
Nat Rev Drug Discov. 2005 Jul;4(7):581-93
pubmed: 16052241
Acta Biomater. 2016 Sep 1;41:293-301
pubmed: 27262740
Biochim Biophys Acta. 1990 Mar 30;1023(1):124-32
pubmed: 2317491
J Pediatr Surg. 2001 Dec;36(12):1785-91
pubmed: 11733907
Biomaterials. 2014 Sep;35(27):7909-18
pubmed: 24952980
J Biol Chem. 2009 Apr 24;284(17):11579-89
pubmed: 19261618
BETA. 1998 Oct;:5
pubmed: 11365993
Genes (Basel). 2013 Sep 10;4(3):457-84
pubmed: 24705213
Curr Opin Biotechnol. 2010 Oct;21(5):640-5
pubmed: 20674331
Mol Cell Ther. 2014 Sep 10;2:27
pubmed: 26056594
Curr Opin Genet Dev. 2020 Dec;65:112-116
pubmed: 32623324
Br J Pharmacol. 2018 Sep;175(18):3640-3655
pubmed: 29953580
Mol Ther. 2010 Mar;18(3):561-9
pubmed: 20010917
Biol Pharm Bull. 2005 Apr;28(4):565-8
pubmed: 15802787
Eur J Pharm Biopharm. 2021 Aug;165:279-292
pubmed: 34033881
Somat Cell Mol Genet. 1986 Nov;12(6):555-66
pubmed: 3024331
J Control Release. 2016 Dec 28;244(Pt B):149-156
pubmed: 27491881
Int J Mol Sci. 2020 Jul 16;21(14):
pubmed: 32708710
J Biol Chem. 1988 Nov 5;263(31):16274-82
pubmed: 3182792
Eur J Gastroenterol Hepatol. 2006 Sep;18(9):957-63
pubmed: 16894308
Oncol Lett. 2014 Dec;8(6):2577-2580
pubmed: 25360171
Curr Med Chem. 2017;24(26):2809-2826
pubmed: 28260512
AAPS PharmSci. 2002;4(3):E12
pubmed: 12423061
Adv Biomed Res. 2012;1:27
pubmed: 23210086
Biochem Pharmacol. 2013 Dec 1;86(11):1541-54
pubmed: 24070653
Adv Genet. 2015;89:1-24
pubmed: 25620006
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1095-103
pubmed: 20231071
Eur J Pharm Sci. 2003 Mar;18(3-4):211-20
pubmed: 12659932
Biochem Pharmacol. 2021 Jul;189:114371
pubmed: 33338475
Nat Rev Drug Discov. 2020 Oct;19(10):673-694
pubmed: 32782413
Pharmaceutics. 2021 Dec 03;13(12):
pubmed: 34959348
Methods Mol Biol. 2016;1445:33-43
pubmed: 27436311
Mol Pharm. 2014 Jan 6;11(1):254-64
pubmed: 24251728
Biotechnol J. 2015 Sep;10(9):1370-89
pubmed: 26037687
Expert Opin Pharmacother. 2005 Jul;6(8):1421-3
pubmed: 16013991
Oligonucleotides. 2006 Summer;16(2):196-201
pubmed: 16764543
Methods Enzymol. 1987;153:3-11
pubmed: 3323803
Gastric Cancer. 2003;6(4):217-24
pubmed: 14716515
Gene Ther. 2003 Jun;10(12):999-1003
pubmed: 12776156